Advertisement
"We are very excited about our new clinical data on AXL1717 and pleasedto be able to present them at this important scientific meeting" says JohanHarmenberg, CEO of Axelar AB. "Of particular interest is that even though theclinical trial so far was not designed to demonstrate efficacy, a number ofpatients show signs of tumor necrosis on PET (positron emission tomography).Targeting cancer cells with AXL1717 instead of conventional cytotoxicchemotherapy may become an effective and well-tolerated treatment alternativefor cancer patients in the future".
Advertisement
About AXL1717, the IGF-1 Receptor and Cancer
AXL1717 is an orally administered small-molecule IGF-1 receptor inhibitorwith no effect on the important and almost identical insulin receptor.Pre-clinical data on AXL1717 have shown an extraordinary anti-tumor efficacyin animal models, including complete regression of a wide range of humancancers.
The IGF-1 receptor is a validated target for anticancer treatment, thereceptor being crucial for the survival and growth of malignant cells but notfor normal cells.
Globally more than 12 million people are diagnosed with cancer everyyear. Cancer causes annually the death of about 8 million people. Although anumber of cancer drugs have been launched over the last decade, many cancersstill lack an effective therapy. This, together with the fact that manytreatments cause severe side effects, highlights the strong medical need fornew selective anticancer drugs.
About Axelar AB
Axelar AB is a Swedish biotech company founded in 2003 and based onresearch performed at Karolinska Institutet, Stockholm, Sweden. The companyfocuses its activities on research related to IGF-1 receptor inhibitors andtheir applications in important human diseases, particularly cancer. Thebusiness strategy is to outlicense projects after successful clinical trials.For more information, please contact: Johan Harmenberg, MD, PhD (CEO Axelar AB) Telephone: +46-705-14-54-53 http://www.axelar.se
SOURCE Karolinska Development AB
